サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：パクスロビドAPIの世界市場規模調査＆予測、タイプ別（純度99％以上、純度99.5％以上）、用途別（COVID-19経口薬、研究用試薬、その他）、地域別分析、2023-2030年
市場調査レポート
商品コード
1290475

パクスロビドAPIの世界市場規模調査＆予測、タイプ別（純度99％以上、純度99.5％以上）、用途別（COVID-19経口薬、研究用試薬、その他）、地域別分析、2023-2030年

Global Paxlovid API Market Size study & Forecast, by Type (Purity 99%~, Purity 99.5%~), by Application (COVID-19 Oral Drugs, Research Reagents, Other) and Regional Analysis, 2023-2030
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
パクスロビドAPIの世界市場規模調査＆予測、タイプ別（純度99％以上、純度99.5％以上）、用途別（COVID-19経口薬、研究用試薬、その他）、地域別分析、2023-2030年
出版日: 2023年06月10日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

パクスロビドは、2種類の抗ウイルス剤を配合した医薬品です。

軽度から中等度のCOVID-19の病気の治療薬として認可されています。製薬業界におけるパクスロビドAPIの需要の増加は、2023年から2030年の予測期間における市場成長の主要因となっています。

パクスロビドAPI市場の成長を加速させると予想される主な主要因は、コビド病の治療に対する製薬業界における需要の増加です。例えば-世界保健機関によると、2020年4月、SARS-CoV-2は209以上の国と地域に広がり、世界中で2,314,621人以上のコロナウイルス確定症例と157,847人の死亡が記録されています。また、政府によるCOVID-19の治療薬の研究開発への資金提供の増加や、ヘルスケア支出の増加が、予測期間中の市場の有利な成長見通しを生み出しています。さらに、高齢化社会の進展と技術の進歩は、市場に明るい展望を生み出しています。しかし、パクスロビドの副作用が、2023年から2030年の予測期間を通じて市場の成長を阻害しています。

パクスロビドAPIの世界市場調査において考慮された主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、生物医学および医薬品業界の研究開発に対する政府による投資の増加などの要因により、収益面で市場を独占しています。アジア太平洋は、技術の入れ替えや継続的な技術革新により、急成長している地域です。

目次

第1章 エグゼクティブサマリー

  • マーケットスナップショット
  • 世界市場・セグメント別市場の推定・予測、2020-2030年
    • パクスロビドAPI市場：地域別、2020-2030年
    • パクスロビドAPI市場：タイプ別、2020-2030年
    • パクスロビドAPI市場：用途別、2020-2030年
  • 主な動向
  • 調査手法
  • 調査の前提条件

第2章 パクスロビドAPIの世界市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 本調査の対象範囲
  • 調査対象年
  • 通貨換算レート

第3章 世界のパクスロビドAPI市場力学

  • パクスロビドAPI市場の影響分析（2020年～2030年）
    • 市場促進要因
      • 製薬業界における需要の増加
      • 政府別研究費の増加
    • 市場の課題
      • パクスロビドの副作用
    • 市場機会
      • 高齢化社会の進展
      • ヘルスケアにおける技術的進歩の拡大

第4章 パクスロビドAPIの世界市場：産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治的
    • 経済的
    • 社会的
    • 技術的
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19の影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの提言と結論

第5章 パクスロビドAPIの世界市場：タイプ別

  • 市場スナップショット
  • パクスロビドAPIの世界市場：タイプ別、実績 - ポテンシャル分析
  • パクスロビドAPIの世界市場、タイプ別、推定・予測2020～2030年
  • パクスロビドAPIの市場、サブセグメント別分析
    • 純度99%以上
    • 純度99.5%以上

第6章 パクスロビドAPIの世界市場：用途別

  • 市場スナップショット
  • パクスロビドAPIの世界市場、用途別、実績 - ポテンシャル分析
  • パクスロビドAPIの世界市場、用途別、推定・予測2020-2030
  • パクスロビドAPIの市場、サブセグメント別分析
    • COVID-19経口薬
    • 研究用試薬
    • その他

第7章 パクスロビドAPIの世界市場：流通チャネル別

  • 市場スナップショット
  • パクスロビドAPIの世界市場、流通チャネル別、実績 - ポテンシャル分析

第8章 パクスロビドAPIの世界市場：地域別分析

  • 上位の主要国
  • 上位新興国
  • パクスロビドAPIの世界市場、地域別市場スナップショット
  • 北米
    • 米国
      • タイプ別推定・予測、2020-2030年
      • 用途別の推定・予測、2020-2030年
    • カナダ
  • 欧州パクスロビドAPI市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋地域のパクスロビドAPI市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカのパクスロビドAPI市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ地域
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第9章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Pfizer Inc
      • 主要情報
      • 概要
      • 財務情報（データの入手が可能な場合のみ）
      • 製品概要
      • 最近の開発状況
    • Merck & Co. Inc.
    • Ridgeback Biotherapeutics LP
    • Cipla Limited
    • Hetero Labs Limited
    • Sun Pharmaceutical Industries Ltd.
    • Laurus Labs Limited
    • Dr. Reddy's Laboratories Ltd.
    • Mylan N.V.
    • Torrent Pharmaceuticals Ltd.

第10章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • バリデーション
    • 出版
  • 調査の特徴
  • 調査の前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Paxlovid API Market, report scope
  • TABLE 2. Global Paxlovid API Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Paxlovid API Market estimates & forecasts by Type 2020-2030 (USD Billion)
  • TABLE 4. Global Paxlovid API Market estimates & forecasts by Application 2020-2030 (USD Billion)
  • TABLE 5. Global Paxlovid API Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 6. Global Paxlovid API Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Paxlovid API Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Paxlovid API Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Paxlovid API Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Paxlovid API Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Paxlovid API Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Paxlovid API Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Paxlovid API Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Paxlovid API Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. U.S. Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. U.S. Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 17. U.S. Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18. Canada Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 19. Canada Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 20. Canada Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. UK Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 22. UK Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 23. UK Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. Germany Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 25. Germany Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 26. Germany Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. France Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 28. France Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 29. France Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. Italy Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 31. Italy Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 32. Italy Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. Spain Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 34. Spain Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 35. Spain Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. RoE Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 37. RoE Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 38. RoE Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. China Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 40. China Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 41. China Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. India Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 43. India Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 44. India Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. Japan Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 46. Japan Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 47. Japan Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. South Korea Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 49. South Korea Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 50. South Korea Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. Australia Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 52. Australia Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 53. Australia Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. RoAPAC Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. Brazil Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 58. Brazil Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 59. Brazil Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. Mexico Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 61. Mexico Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 62. Mexico Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. RoLA Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 64. RoLA Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 65. RoLA Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. Saudi Arabia Paxlovid API Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 67. South Africa Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 68. RoMEA Paxlovid API Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Paxlovid API Market
  • TABLE 70. List of primary sources, used in the study of global Paxlovid API Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Paxlovid API Market, research methodology
  • FIG 2. Global Paxlovid API Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Paxlovid API Market, key trends 2022
  • FIG 5. Global Paxlovid API Market, growth prospects 2023-2030
  • FIG 6. Global Paxlovid API Market, porters 5 force model
  • FIG 7. Global Paxlovid API Market, pest analysis
  • FIG 8. Global Paxlovid API Market, value chain analysis
  • FIG 9. Global Paxlovid API Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Paxlovid API Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Paxlovid API Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Paxlovid API Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Paxlovid API Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Paxlovid API Market, regional snapshot 2020 & 2030
  • FIG 15. North America Paxlovid API Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Paxlovid API Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Paxlovid API Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Paxlovid API Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Paxlovid API Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Paxlovid API Market is valued at approximately USD XXX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Paxlovid is a medicine that combines two antiviral drugs. It is authorized for the treatment of mild to moderate COVID-19 illnesses. The increasing demand for Paxlovid API in the pharmaceutical industry is the key factor responsible for market growth over the forecast period of 2023-2030.

The primary key factor anticipated to accelerate the growth of the Paxlovid API Market is the increasing demand in the pharmaceutical industry for the treatment of Covid illness. For instance- according to the World Health Organization, In Apr 2020, SARS-CoV-2 spread to over 209 countries and territories, with over 2,314,621 confirmed coronavirus cases recorded and 157,847 deaths globally. Also, increasing funding by the government for research and development for medications for COVID-19 and growing healthcare expenditure are creating a lucrative growth prospectus for the market over the forecast period. Moreover, the growing aging population and technological advancements create a positive outlook for the market. However, side effects of Paxlovid stifle market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Paxlovid API Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in terms of revenue owing to factors such as growing investments by the government in research & development in the biomedical and pharmaceuticals industry. Asia-Pacific is the fastest-growing region due to technology replacement and continuous innovations.

Major market player included in this report are:

  • Pfizer Inc
  • Merck & Co. Inc.
  • Ridgeback Biotherapeutics LP
  • Cipla Limited
  • Hetero Labs Limited
  • Sun Pharmaceutical Industries Ltd.
  • Laurus Labs Limited
  • Dr. Reddy's Laboratories Ltd.
  • Mylan N.V.
  • Torrent Pharmaceuticals Ltd.

Recent Developments in the Market:

  • In June 2022, Pfizer has invested $120 million to produce oral treatment for COVID-19, Paxlovid, with the expansion creating more than 250 high-skilled manufacturing jobs at the company's site in Michigan.

Global Paxlovid API Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Type, Application, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
  • The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Type:

  • Purity ≥99%
  • Purity ≥99.5%

By Application:

  • COVID-19 Oral Drugs
  • Research Reagents
  • Other

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Paxlovid API Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Paxlovid API Market, by Type, 2020-2030 (USD Billion)
    • 1.2.3. Paxlovid API Market, by Application, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Paxlovid API Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Paxlovid API Market Dynamics

  • 3.1. Paxlovid API Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing demand in pharmaceutical industry
      • 3.1.1.2. Increasing funding by the government for research
    • 3.1.2. Market Challenges
      • 3.1.2.1. Side effects of Paxlovid
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing aging population
      • 3.1.3.2. Growing technological advancement in healthcare

Chapter 4. Global Paxlovid API Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Paxlovid API Market, by Type

  • 5.1. Market Snapshot
  • 5.2. Global Paxlovid API Market by Type, Performance - Potential Analysis
  • 5.3. Global Paxlovid API Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
  • 5.4. Paxlovid API Market, Sub Segment Analysis
    • 5.4.1. Purity ≥99%
    • 5.4.2. Purity ≥99.5%

Chapter 6. Global Paxlovid API Market, by Application

  • 6.1. Market Snapshot
  • 6.2. Global Paxlovid API Market by Application, Performance - Potential Analysis
  • 6.3. Global Paxlovid API Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
  • 6.4. Paxlovid API Market, Sub Segment Analysis
    • 6.4.1. COVID-19 Oral Drugs
    • 6.4.2. Research Reagents
    • 6.4.3. Other

Chapter 7. Global Paxlovid API Market, by Distribution Channel

  • 7.1. Market Snapshot
  • 7.2. Global Paxlovid API Market by Distribution Channel, Performance - Potential Analysis

Chapter 8. Global Paxlovid API Market, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. Paxlovid API Market, Regional Market Snapshot
  • 8.4. North America Paxlovid API Market
    • 8.4.1. U.S. Paxlovid API Market
      • 8.4.1.1. Type breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
    • 8.4.2. Canada Paxlovid API Market
  • 8.5. Europe Paxlovid API Market Snapshot
    • 8.5.1. U.K. Paxlovid API Market
    • 8.5.2. Germany Paxlovid API Market
    • 8.5.3. France Paxlovid API Market
    • 8.5.4. Spain Paxlovid API Market
    • 8.5.5. Italy Paxlovid API Market
    • 8.5.6. Rest of Europe Paxlovid API Market
  • 8.6. Asia-Pacific Paxlovid API Market Snapshot
    • 8.6.1. China Paxlovid API Market
    • 8.6.2. India Paxlovid API Market
    • 8.6.3. Japan Paxlovid API Market
    • 8.6.4. Australia Paxlovid API Market
    • 8.6.5. South Korea Paxlovid API Market
    • 8.6.6. Rest of Asia Pacific Paxlovid API Market
  • 8.7. Latin America Paxlovid API Market Snapshot
    • 8.7.1. Brazil Paxlovid API Market
    • 8.7.2. Mexico Paxlovid API Market
  • 8.8. Middle East & Africa Paxlovid API Market
    • 8.8.1. Saudi Arabia Paxlovid API Market
    • 8.8.2. South Africa Paxlovid API Market
    • 8.8.3. Rest of Middle East & Africa Paxlovid API Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. Pfizer Inc
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Development
    • 9.3.2. Merck & Co. Inc.
    • 9.3.3. Ridgeback Biotherapeutics LP
    • 9.3.4. Cipla Limited
    • 9.3.5. Hetero Labs Limited
    • 9.3.6. Sun Pharmaceutical Industries Ltd.
    • 9.3.7. Laurus Labs Limited
    • 9.3.8. Dr. Reddy's Laboratories Ltd.
    • 9.3.9. Mylan N.V.
    • 9.3.10. Torrent Pharmaceuticals Ltd.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption